Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Calidi BiotherapeuticsCLDI +3.25%12 3-Year Book Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Calidi Biotherapeutics ranks worse than 88417.24% on this metric.
During the past 12 months, Calidi Biotherapeutics's average Book Value per Share Growth Rate was -84.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Calidi Biotherapeutics was 28.40% per year. The lowest was 28.40% per year. And the median was 28.40% per year.
Calidi Biotherapeutics (AMEX:CLDI) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Calidi Biotherapeutics 3-Year Book Growth Rate Related Terms
CLDI vs BBLG, CDT, BPTH: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's 3-Year Book Growth Rate falls into.
Calidi Biotherapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 0.00% mean?
Calidi Biotherapeutics (CLDI) has a 3-Year Book Growth Rate of 0.00% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Calidi Biotherapeutics and its competitors. Over the past decade, Calidi Biotherapeutics' 3-Year Book Growth Rate has ranged from 28.40 to 28.40. According to the industry distribution chart, Calidi Biotherapeutics ranks #999999 out of 1131 companies in the Biotechnology industry.
Is Calidi Biotherapeutics' 3-Year Book Growth Rate too high?
Calidi Biotherapeutics' current 3-Year Book Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 28.40 to a high of 28.40. Based on the distribution chart, Calidi Biotherapeutics ranks #999999 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' 3-Year Book Growth Rate compare to BBLG and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #999999 out of 1131 companies for 3-Year Book Growth Rate. This places Calidi Biotherapeutics in the lower half of its industry. Historically, Calidi Biotherapeutics' own 3-Year Book Growth Rate has ranged from 28.40 to 28.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current 3-Year Book Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
